Oğuz Bilgi

526 total citations
37 papers, 397 citations indexed

About

Oğuz Bilgi is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Oğuz Bilgi has authored 37 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Immunology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Oğuz Bilgi's work include Immune Cell Function and Interaction (5 papers), Immunotherapy and Immune Responses (4 papers) and Inflammatory Biomarkers in Disease Prognosis (4 papers). Oğuz Bilgi is often cited by papers focused on Immune Cell Function and Interaction (5 papers), Immunotherapy and Immune Responses (4 papers) and Inflammatory Biomarkers in Disease Prognosis (4 papers). Oğuz Bilgi collaborates with scholars based in Türkiye, Serbia and Cambodia. Oğuz Bilgi's co-authors include Bülent Karagöz, Alpaslan Özgün, Alev Akyol Erikçi, Ahmet Öztürk, Aptullah Haholu, Orhan Türken, Serkan Çelik, Özkan Sayan, Mahmut Gümüş and Mustafa Yaylacı and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and BMC Cancer.

In The Last Decade

Oğuz Bilgi

30 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oğuz Bilgi Türkiye 11 151 145 79 72 46 37 397
Bülent Karagöz Türkiye 11 168 1.1× 155 1.1× 84 1.1× 75 1.0× 49 1.1× 40 439
Luciana Tanca Italy 7 158 1.0× 118 0.8× 101 1.3× 56 0.8× 69 1.5× 9 401
K. Oliva Australia 8 164 1.1× 67 0.5× 120 1.5× 67 0.9× 50 1.1× 13 431
Valentina Iannizzotto United Kingdom 8 137 0.9× 154 1.1× 98 1.2× 27 0.4× 20 0.4× 14 443
Jiangdong Xiang China 10 107 0.7× 71 0.5× 138 1.7× 115 1.6× 47 1.0× 25 371
Ludmila Lozneanu Romania 12 66 0.4× 85 0.6× 121 1.5× 40 0.6× 39 0.8× 66 415
Jingjing Guo China 13 96 0.6× 67 0.5× 159 2.0× 97 1.3× 75 1.6× 49 460
Yung Jue Bang South Korea 10 124 0.8× 55 0.4× 149 1.9× 60 0.8× 86 1.9× 30 412
Christian Dannecker Germany 12 118 0.8× 84 0.6× 116 1.5× 74 1.0× 33 0.7× 58 459
Jiang Xue China 11 62 0.4× 151 1.0× 93 1.2× 38 0.5× 44 1.0× 36 394

Countries citing papers authored by Oğuz Bilgi

Since Specialization
Citations

This map shows the geographic impact of Oğuz Bilgi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oğuz Bilgi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oğuz Bilgi more than expected).

Fields of papers citing papers by Oğuz Bilgi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oğuz Bilgi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oğuz Bilgi. The network helps show where Oğuz Bilgi may publish in the future.

Co-authorship network of co-authors of Oğuz Bilgi

This figure shows the co-authorship network connecting the top 25 collaborators of Oğuz Bilgi. A scholar is included among the top collaborators of Oğuz Bilgi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oğuz Bilgi. Oğuz Bilgi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Erikçi, Alev Akyol, Bülent Karagöz, & Oğuz Bilgi. (2016). Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura. Turkish Journal of Hematology. 33(2). 153–155. 2 indexed citations
2.
Karagöz, Bülent, et al.. (2015). Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer. SHILAP Revista de lepidopterología. 11(1). 48–51. 1 indexed citations
3.
Özgün, Alpaslan, et al.. (2014). Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy. Asian Pacific Journal of Cancer Prevention. 15(15). 6421–6423. 44 indexed citations
4.
Karagöz, Bülent, et al.. (2014). HLA-G in Testicular Germ Cell Tumors. Oncology Research and Treatment. 37(5). 245–248. 5 indexed citations
6.
Özgün, Alpaslan, et al.. (2014). Malignant melanoma and papillary thyroid carcinoma that were diagnosed concurrently and treated simultaneously: A case report. Oncology Letters. 9(1). 468–470. 7 indexed citations
7.
Özgün, Alpaslan, et al.. (2013). Clinicopathological Features and Survival of Young Turkish Patients with Testicular Germ Cell Tumors. Asian Pacific Journal of Cancer Prevention. 14(11). 6889–6892. 6 indexed citations
8.
Karagöz, Bülent, et al.. (2013). Immunoregulatory Function of HLA-G in Gastric Cancer. Asian Pacific Journal of Cancer Prevention. 14(12). 7681–7684. 47 indexed citations
9.
Özgün, Alpaslan, et al.. (2013). MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer. Oncology Research and Treatment. 36(3). 115–118. 26 indexed citations
10.
Çetinkaya, Hakkı, et al.. (2012). Nesfatin-1 in advanced lung cancer patients with weight loss. Regulatory Peptides. 181. 1–3. 16 indexed citations
11.
Karagöz, Bülent, Alev Akyol Erikçi, Özlem Karabudak, et al.. (2010). The Diagnosis Of Non Hodgkin Lymphoma In An Epidermodysplasia\nVerruciformis Patient. Bioline International (Bioline International). 1 indexed citations
12.
Önem, Yalçın, Osman Metin İpçioğlu, Aptullah Haholu, et al.. (2009). Posttreatment with Aminoguanidine Attenuates Renal Ischemia/Reperfusion Injury in Rats. Renal Failure. 31(1). 50–53. 13 indexed citations
13.
Karagöz, Bülent, Oğuz Bilgi, Ahmet Alacacıoğlu, et al.. (2009). Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer. Medical Oncology. 27(2). 199–202. 10 indexed citations
14.
Karagöz, Bülent, Oğuz Bilgi, Mahmut Gümüş, et al.. (2009). CD8+CD28− cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Medical Oncology. 27(1). 29–33. 66 indexed citations
15.
Karagöz, Bülent, et al.. (2009). Cerebrovascular Accident After Chemotherapy for Testicular Cancer. Military Medicine. 174(3). 320–321. 6 indexed citations
16.
Bilgi, Oğuz, Bülent Karagöz, Orhan Türken, et al.. (2008). Peripheral blood gamma-delta T cells in advanced-stage cancer patients. Advances in Therapy. 25(3). 218–224. 4 indexed citations
17.
Karagöz, Bülent, Selami Süleymanoğlu, Günalp Uzun, et al.. (2008). Hyperbaric Oxygen Therapy Does Not Potentiate Doxorubicin‐Induced Cardiotoxicity in Rats. Basic & Clinical Pharmacology & Toxicology. 102(3). 287–292. 24 indexed citations
18.
Ay, Hakan, Günalp Uzun, Yalçın Önem, et al.. (2007). Effect of Hyperbaric Oxygen on Cyclosporine-Induced Nephrotoxicity and Oxidative Stress in Rats. Renal Failure. 29(4). 495–501. 10 indexed citations
19.
Atasoyu, Enes Murat, Şenol Yıldız, Maide Çimşit, et al.. (2006). Investigation of the Effect of Hyperbaric Oxygen on Experimental Cyclosporine Nephrotoxicity. Basic & Clinical Pharmacology & Toxicology. 98(2). 150–154. 9 indexed citations
20.
Atasoyu, Enes Murat, Şenol Yıldız, Oğuz Bilgi, et al.. (2004). Investigation of the role of hyperbaric oxygen therapy in cisplatin-induced nephrotoxicity in rats. Archives of Toxicology. 79(5). 289–293. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026